The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome. METHODS: We enrolled 4128 patients who were at least 60 years of age and had New York Heart Association class II, III, or IV heart failure and an ejection fraction of at least 45% and randomly assigned them to receive 300 mg of irbesartan or placebo per day. The primary composite outcome was death from any cause or hospitalization for a cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any cause and from cardiovascular causes, and quality of life. RESULTS: During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P=0.35). Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard ratio, 1.00; 95% CI, 0.88 to 1.14; P=0.98). Rates of hospitalization for cardiovascular causes that contributed to the primary outcome were 70.6 and 74.3 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P=0.44). There were no significant differences in the other prespecified outcomes. CONCLUSIONS: Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“once weekly subcutaneous injection with semaglutide resulted in a marked and sustained weight loss of >15% in patients who are overweight or obese.”
From The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,209
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Paulus, W. J., Tschöpe, C., Sanderson, J. E., Rusconi, C., Flachskampf, F. A., Rademakers, F. E., Marino, P. N., Smiseth, O. A., Keulenaer, G. W. D., Leite-Moreira, A. F., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm037 · Cited by 2,646
Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study
Bhatia, R. S., Tu, J. V., Lee, D. S., Austin, P. C., Fang, J., Haouzi, A., Gong, Y., & Liu, P. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051530 · Cited by 1,959
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,001
Shen, L., Jhund, P. S., Docherty, K. F., Petrie, M. C., Anand, I. S., Carson, P. E., Desai, A. S., Granger, C. B., Michel Komajda, N., McKelvie, R. S., et al. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.12.006 · Cited by 27
Self-citationDevice-based treatment options for heart failure with preserved ejection fraction
Miyagi, C., Miyamoto, T., Karimov, J. H., Starling, R. C., & Fukamachi, K. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10067-5 · Cited by 27
Wang, M., Shan, Y., Wu, C., Cao, P., Sun, W., Han, J., Shen, L., Chen, J., Yu, P., & Chen, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.626375 · Cited by 27
Mooney, L., Goodyear, C. S., Chandra, T., Kirschner, K., Copland, M., Petrie, M. C., & Lang, N. N. (2021) · Clinical Science · doi:10.1042/cs20200306 · Cited by 28
Phenomapping Heart Failure with Preserved Ejection Fraction Using Machine Learning Cluster Analysis
Galli, E., Bourg, C., Kosmala, W., Oger, E., & Donal, E. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.010 · Cited by 31
Gibb, A., Murray, E. K., Eaton, D., Huynh, A. T., Tomar, D., Garbincius, J. F., Kolmetzky, D. W., Berretta, R. M., Wallner, M., Houser, S. R., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.07.004 · Cited by 26
Phenomics and Robust Multiomics Data for Cardiovascular Disease Subtyping
Maiorino, E., & Loscalzo, J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318892 · Cited by 34
Doiron, J. E., Li, Z., Yu, X., LaPenna, K. B., Quiriarte, H. D., Allerton, T. D., Koul, K., Malek, A. J., Shah, S. J., Sharp, T. E., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032646 · Cited by 25
Renin Angiotensin System and Cardiovascular Disease
DEMELLO, W., & Frohlich, E. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-186-8 · Cited by 27
Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina
Badar, A., Moreno, A. C. P., Hawkins, N. M., Jhund, P. S., Brunton, A. P. T., Anand, I. S., McKelvie, R. S., Michel Komajda, N., Zile, M. R., Carson, P. E., et al. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.002024 · Cited by 27
Self-citationOutpatient Management of Heart Failure in the United States, 2006–2008
Mosalpuria, K., Agarwal, S. K., Yaemsiri, S., Pierre-Louis, B., Saba, S., Alvarez, R., & Russell, S. D. (2014) · Texas Heart Institute Journal · doi:10.14503/thij-12-2947 · Cited by 27
Comparing angiotensin II receptor blockers on benefits beyond blood pressure
Siragy, H. M. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0028-3 · Cited by 27
Thomopoulos, C., Parati, G., & Zanchetti, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001548 · Cited by 29
Lee, M. S., Duan, L., Clare, R., Hekimian, A., Spencer, H. T., & Chen, W. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.04.027 · Cited by 27
Exercise in Heart Failure—What Is the Optimal Dose to Improve Pathophysiology and Exercise Capacity?
Schindler, M., Adams, V., & Halle, M. (2019) · Current Heart Failure Reports · doi:10.1007/s11897-019-00428-z · Cited by 27
Jang, S., Ogunmoroti, O., Ndumele, C. E., Zhao, D., Rao, V. N., Fashanu, O. E., Tibuakuu, M., Otvos, J. D., Benson, E., Ouyang, P., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007067 · Cited by 27
Rieger, A. C., Bagno, L., Salerno, A. G., Florea, V., Rodriguez, J. E., Rosado, M., Turner, D., Dulce, R. A., Takeuchi, L. M., Kanashiro‐Takeuchi, R. M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019835118 · Cited by 27
Therapeutic Strategies for Diastolic Dysfunction: A Clinical Perspective
Ha, J., & Oh, J. K. (2009) · Journal of Cardiovascular Ultrasound · doi:10.4250/jcu.2009.17.3.86 · Cited by 27
Defining HFpEF: where do we draw the line?
Borlaug, B. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv561 · Cited by 27
Sonaglioni, A., Lonati, C., Tescaro, L., Nicolosi, G. L., Proietti, M., Lombardo, M., & Harari, S. A. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-02025-4 · Cited by 26
Pandey, A., Darden, D. J., & Berry, J. D. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.05.007 · Cited by 27
2013 ESH/ESC GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION
Mancia, G., Fagard, R. H., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T. C., Cífková, R., Backer, G. D., Dominiczak, A. F., et al. (2014) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2014-1-7-94 · Cited by 26
Heart Failure with Preserved Ejection Fraction – A Review
Smiseth, O. A., Opdahl, A., Boe, E., & Skulstad, H. (2012) · European Cardiology Review · doi:10.15420/ecr.2012.8.3.186 · Cited by 26
Lysophosphatidic acid enhances survival of human CD34+ cells in ischemic conditions
Kostić, I., Fidalgo-Carvalho, I., Aday, S., Vazão, H., Carvalheiro, T., Grãos, M., Duarte, A., Cardoso, C. M. P., Gonçalves, L. M. M., Carvalho, L., et al. (2015) · Scientific Reports · doi:10.1038/srep16406 · Cited by 26
Lumpers and splitters: the bumpy road to precision medicine
Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz644 · Cited by 27
Interrelation between heart failure with preserved ejection fraction and renal impairment
Joslin, J. R., Lioudaki, E., & Androulakis, E. S. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2302069 · Cited by 27
Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial
Litwin, S. E., Komtebedde, J., Seidler, T., Borlaug, B. A., Winkler, S., Solomon, S. D., Eicher, J.-C., Mazimba, S., Khawash, R., Sverdlov, A. L., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3092 · Cited by 26
for Effect of ARB/Diuretics on Diastolic Function in Patients with Hypertension (EDEN) trial investigators, Ito, H., Ishii, K., Kihara, H., Kasayuki, N., Nakamura, F., Shimada, K., Fukuda, S., Iwakura, K., & Yoshikawa, J. (2011) · Hypertension Research · doi:10.1038/hr.2011.169 · Cited by 26
Toh, N., Nishii, N., Nakamura, K., Tada, T., Oe, H., Nagase, S., Kohno, K., Morita, H., KUSANO, K. F., & Ito, H. (2012) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.111.970285 · Cited by 26
Echocardiographic evaluation of diastolic heart failure
Lo, Q., & Thomas, L. (2010) · Australasian Journal of Ultrasound in Medicine · doi:10.1002/j.2205-0140.2010.tb00214.x · Cited by 26
Zhang, L., Liebelt, J., Madan, N., Shan, J., & Taub, C. C. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.03.005 · Cited by 26
Clerico, A., Zaninotto, M., Passino, C., & Plebani, M. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0840 · Cited by 26
Treatment of diastolic dysfunction in hypertension
Ginelli, P., & Bella, J. N. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.04.016 · Cited by 25
Heart failure in the elderly: advances and challenges
Jugdutt, B. I. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.36 · Cited by 26
Characteristics and outcome for heart failure patients with mid-range ejection fraction
Wang, N., Hales, S., Barin, E. S., & Tofler, G. H. (2018) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000653 · Cited by 25
Nandini, B., Nagaraja, G., Prakash, H. S., & Hariparsad, P. (2021) · Biological Control · doi:10.1016/j.biocontrol.2021.104550 · Cited by 25
Renal Dysfunction and Heart Failure with Preserved Ejection Fraction
Ananthram, M. G., & Gottlieb, S. S. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.03.005 · Cited by 28
Polypharmacy and excessive polypharmacy in octogenarians and older acutely hospitalized patients
Strehblow, C., Smeikal, M., & Fasching, P. (2014) · Wiener klinische Wochenschrift · doi:10.1007/s00508-013-0485-1 · Cited by 25
Heart Failure With Preserved Ejection Fraction
Desai, A. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.075 · Cited by 25
Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
Lang, C. C., & Singh, J. S. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s55630 · Cited by 24
Long-term use and tolerability of irbesartan for control of hypertension
Burnier, M., Forni, V., Wuerzner, G., & Pruijm, M. T. (2011) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s12211 · Cited by 25
A Systematic Review of Angiotensin Receptor Blockers in Preventing Stroke
Lu, G.-C., Cheng, J.-W., Zhu, K., Ma, X., Shen, F., & Su, D. (2009) · Stroke · doi:10.1161/strokeaha.109.559989 · Cited by 25
Chung, C. S., & Campbell, K. S. (2013) · Physiological Reports · doi:10.1002/phy2.158 · Cited by 25
Hummel, Y. M., Klip, I. T., de Jong, R. M., Pieper, P. G., van Veldhuisen, D. J., & Voors, A. A. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0141-y · Cited by 25
Miyoshi, T., Nakamura, K., Miura, D., Yoshida, M., Saito, Y., Akagi, S., Ohno, Y., Kondo, M., & Ito, H. (2018) · Cardiology Journal · doi:10.5603/cj.a2018.0048 · Cited by 25
Sato, Y., Yoshihisa, A., Oikawa, M., Nagai, T., Yoshikawa, T., Saito, Y., Yamamoto, K., Takeishi, Y., & Anzai, T. (2019) · Journal of Cardiology · doi:10.1016/j.jjcc.2019.01.005 · Cited by 26
Coletta, A. P., Clark, A. L., & Cleland, J. G. F. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfn047 · Cited by 25
Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF
Rosano, G. M. C., Vitale, C., & Spoletini, I. (2024) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0058 · Cited by 29
Kondo, T., Campbell, R. T., Jhund, P. S., Anand, I. S., Carson, P. E., Lam, C. S. P., Shah, S. J., Vaduganathan, M., Zannad, F. M., Zile, M. R., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.027 · Cited by 33
Self-citationSystolic Blood Pressure and Pulse Pressure in Heart Failure
Lu, H. Y., Kondo, T., Claggett, B. L., Vaduganathan, M., Neuen, B. L., Beldhuis, I. E., Jhund, P. S., Causland, F. R. M., Anand, I. S., Pfeffer, M. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.007 · Cited by 32
Self-citationGarg, N., Senthilkumar, A., Nusair, M. B., Goyal, N., Garg, R. K., & Alpert, M. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31828c586e · Cited by 26
After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction
Desai, A. S., & Jhund, P. S. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw114 · Cited by 23
Xia, C., Chu, P., Liu, Y., Qu, X., Gao, X., Wang, Z., Dong, J., Chen, S., & Zhang, J. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-019-0182-2 · Cited by 24
Zhou, H., Peng, W., Li, F., Wang, Y., Wang, B., Ding, Y., Lin, Q., Zhao, Y., Pan, G., & Wang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.875327 · Cited by 31
MacDonald, B. J., Virani, S., Zieroth, S. R., & Turgeon, R. D. (2023) · CJC Open · doi:10.1016/j.cjco.2023.05.008 · Cited by 25
Investigation and management of congestive heart failure
Arroll, B., Doughty, R. N., & Andersen, V. (2010) · BMJ · doi:10.1136/bmj.c3657 · Cited by 25
Heart Failure with Preserved Ejection Fraction in Older Adults
Chen, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.01.038 · Cited by 23
Patel, H. C., Hayward, C., Dungu, J. N., Papadopoulou, S. A., Saidmeerasah, A., Ray, R., Mario, C. D., Shanmugam, N., Cowie, M., & Anderson, L. J. (2017) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2017.04.006 · Cited by 24
Thorvaldsen, T., Claggett, B. L., Shah, A. M., Cheng, S. C., Agarwal, S. K., Wruck, L. M., Chang, P. P., Rosamond, W. D., Lewis, E. F., Desai, A. S., et al. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.003992 · Cited by 24
Contemporary Management of Heart Failure in the Elderly
Osmanska, J., & Jhund, P. S. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0625-4 · Cited by 26
Dzhioeva, O. N., & Belyavskiy, E. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s207117 · Cited by 26
Matsumoto, S., Henderson, A. D., Shen, L., Kondo, T., Yang, M., Campbell, R. T., Anand, I. S., de Boer, R. A., Desai, A. S., Lam, C. S. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3383 · Cited by 25
Self-citationWhat Is Cardiometabolic HFpEF and How Can We Study it Preclinically?
Daou, D., Tong, D., Schiattarella, G. G., Gillette, T. G., & Hill, J. A. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.009 · Cited by 32
Heart Failure with Preserved Ejection Fraction: The Impact of Stricter Definitions
Patel, H. C., Hayward, C., Mario, C. D., Cowie, M., Lyon, A. R., & Rosen, S. D. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.106 · Cited by 23
Jessup, J. A., Wang, H., MacNamara, L. M., Presley, T. D., Kim‐Shapiro, D. B., Zhang, L., Chen, A. F., & Groban, L. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318280589a · Cited by 23
Heart failure with preserved ejection fraction
Liu, Y., Haddad, T., & Dwivedi, G. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32835c5492 · Cited by 23
The cardiovascular continuum refined: A hypothesis
Volpe, M., Camm, A. J., Coca, A., & Unger, T. (2010) · Blood Pressure · doi:10.3109/08037051.2010.481072 · Cited by 23
Exercise-Based Rehabilitation for Heart Failure: Clinical Evidence
Ding, R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-4304-8_3 · Cited by 23
Fukuta, H., Goto, T., Wakami, K., Kamiya, T., & Ohte, N. (2018) · Heart and Vessels · doi:10.1007/s00380-018-1279-1 · Cited by 23
Blum, M., Hashemi, D., Motzkus, L. A., Neye, M., Đorđević, A., Zieschang, V., Zamani, S. M., Lapinskas, T., Runte, K., Kelm, M., et al. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00111 · Cited by 23
Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
Dhore-Patil, A., Thannoun, T., Samson, R., & Jemtel, T. H. L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.785879 · Cited by 27
Sudden Death and Ventricular Arrhythmias in Heart Failure With Preserved Ejection Fraction
Cho, J. H. (2022) · Korean Circulation Journal · doi:10.4070/kcj.2021.0420 · Cited by 26
Filardi, P. P., Paolillo, S., Agostoni, P., Basile, C., Basso, C., Barillà, F., Correale, M., Curcio, A., Mancone, M., Merlo, M., et al. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.04.006 · Cited by 23
Wang, N., Evans, J., Sawant, S., Sindone, J., & Lal, S. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10275-1 · Cited by 25
Wu, H., Tang, L., Wang, X., Li, L.-P., Chen, X., He, Y., Yang, D., Shi, Y., Shou, J., Zhang, Z.-S., et al. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01025-y · Cited by 24
Charalampopoulos, A. F., Howard, L., Tzoulaki, I., Gin‐Sing, W., Grapsa, J., Wilkins, M. R., Davies, R. J., Nihoyannopoulos, P., Connolly, S. B., & Gibbs, J. S. R. (2014) · Pulmonary Circulation · doi:10.1086/678512 · Cited by 23
Agarwal, V., Briasoulis, Α., & Messerli, F. H. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9329-8 · Cited by 23
Characteristics of heart failure associated with the Great East Japan Earthquake
Nakamura, A., Satake, H., Abe, A., Kagaya, Y., Kohzu, K., Sato, K., Nakajima, S., Fukui, S., Endo, H., Takahashi, T., et al. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.02.015 · Cited by 23
Kapłon‐Cieślicka, A., Tymińska, A., Peller, M., Balsam, P., Ozierański, K., Galas, M., Marchel, M., Crespo‐Leiro, M. G., Maggioni, A. P., Dróżdż, J., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.05.046 · Cited by 23
Polsinelli, V. B., & Shah, S. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1288717 · Cited by 23
Targets for Heart Failure With Preserved Ejection Fraction
Nanayakkara, S., & Kaye, D. M. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.723 · Cited by 23
Almeida, P., Rodrigues, J., Lourenço, P., Maciel, M. J., & Bettencourt, P. (2018) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000651 · Cited by 23
Heart Failure Epidemiology and Treatment in Primary Care: A Retrospective Cross-Sectional Study
Rachamin, Y., Meier, R., Rosemann, T. J., Flammer, A. J., & Chmiel, C. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13105 · Cited by 23
Rasalam, R. R., Sindone, A. P., Deed, G., Audehm, R. G., & Atherton, J. J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15205 · Cited by 26
Traditional Heart Failure Medications and Sudden Cardiac Death Prevention
Chekakie, M. O. A. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413491496 · Cited by 22
Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease
Singhania, N., Bansal, S. K., Mohandas, S., Nimmatoori, D. P., Ejaz, A. A., & Singhania, G. (2020) · Drugs in Context · doi:10.7573/dic.2020-7-3 · Cited by 24
Bekfani, T., Nisser, J., Derlien, S., Hamadanchi, A., Fröb, E., Dannberg, G., Lichtenauer, M., Smolenski, U. C., Lehmann, G., Möbius‐Winkler, S., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13468 · Cited by 22
Lechner, K., Scherr, J., Lorenz, E., Lechner, B., Haller, B., Krannich, A., Halle, M., Wachter, R., Duvinage, A., & Edelmann, F. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01925-9 · Cited by 21
Maryniak, A., Maisuradze, N., Ahmed, R., Biskupski, P., Joseph, J., & Budzikowski, A. S. (2022) · Cardiology Journal · doi:10.5603/cj.a2022.0051 · Cited by 22
The controversial role of beta-blockers in heart failure with preserved ejection fraction
Wernhart, S., Παπαθανασίου, Μ., Rassaf, T., & Luedike, P. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108356 · Cited by 23
Current Controversies in Heart Failure with a Preserved Ejection Fraction
MacIver, D. H. (2009) · Future Cardiology · doi:10.2217/fca.09.56 · Cited by 21
Cleland, J. G. F., & Cullington, D. (2009) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.859322 · Cited by 22
Multimorbidity in Older Adults with Heart Failure
Dharmarajan, K., & Dunlay, S. M. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.01.002 · Cited by 24
Cannon, J. A., Shen, L., Jhund, P. S., Anand, I. S., Michel Komajda, N., McKelvie, R. S., Zile, M. R., Carson, P. E., & McMurray, J. J. V. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.547 · Cited by 22
Self-citationDézsi, C. A., & Szentes, V. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0185-0 · Cited by 23
Treatment of Hyperkalemia in Heart Failure
DeFilippis, E. M., & Desai, A. S. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0341-0 · Cited by 23
Shah, S. J. (2019) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2019.08.002 · Cited by 23
Blocking aldosterone in heart failure
Shafiq, M. M., & Miller, A. B. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709341300 · Cited by 22
Heart Failure with a Normal Ejection Fraction
Sanderson, J. E., & Tan, Y. T. (2010) · Springer eBooks · doi:10.1007/978-1-84996-153-0_5 · Cited by 22
Choi, E., Hwang, S. H., Yoon, Y. W., Park, C. H., Paek, M. Y., Greiser, A., Chung, H., Yoon, J.-H., Kim, J., Min, P., et al. (2013) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-15-11 · Cited by 22
Metadata
- Authors
- Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., & Ptaszynska, A.
- Affiliations
- San Francisco VA Medical Center (US)
- Georgetown University (US)
- University of Glasgow (GB)
- Hamilton Health Sciences (CA)
- Medical University of South Carolina (US)
- University of Wisconsin–Madison (US)
- Bristol-Myers Squibb (United States) (US)
- Sanofi (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-12-04
- Volume
- 359
- Issue
- 23
- Pages
- 2456-2467
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068519950
- Cited by
- 1,960
- References
- 37
- Citations by year
- 2026: 61 · 2025: 72 · 2024: 92 · 2023: 94 · 2022: 128 · 2021: 120 · 2020: 123 · 2019: 118 · 2018: 117 · 2017: 138 · 2016: 105 · 2015: 127 · 2014: 119 · 2013: 122 · 2012: 109
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- irbesartan, heart failure with preserved ejection fraction, angiotensin receptor blockers, cardiovascular mortality, cardiovascular hospitalization, heart failure hospitalization, quality of life, elderly patients
- MeSH terms
- Irbesartan, Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiovascular Diseases, Drug Therapy, Combination, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Quality of Life, Stroke Volume, Tetrazoles, Proportional Hazards Models, Treatment Failure, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
